Evidence map›Paper›PMID 32960928›Full record

ArticlePloS one2020

The use of 4-Hexylresorcinol as antibiotic adjuvant.

Y A Nikolaev, A V Tutel'yan, N G Loiko, J Buck, S V Sidorenko, I Lazareva, V Gostev, O Y Manzen'yuk, I G Shemyakin, R A Abramovich and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Antibiotic persistence of intracellular Brucella abortus.PLoS neglected tropical diseases · 2022
    Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Y A NikolaevFederal Research Centre "Fundamentals of Biotechnology", Russian Academy of Sciences, Moscow, Russia.
A V Tutel'yanCentral Research Institute of Epidemiology of Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) and I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.ORCID 0000-0002-2706-6689
N G LoikoFederal Research Centre "Fundamentals of Biotechnology", Russian Academy of Sciences, Moscow, Russia.
J BuckDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID 0000-0002-4676-3113
S V SidorenkoPediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia.
I LazarevaPediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia.
V GostevPediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia.
O Y Manzen'yukState Research Center for Applied Microbiology and Biotechnology of Russian Federal Service for Surveillance on Consumer Rights Protection and Human Welfare (Rospotrebnadzor), Obolensk, Russia.
I G ShemyakinState Research Center for Applied Microbiology and Biotechnology of Russian Federal Service for Surveillance on Consumer Rights Protection and Human Welfare (Rospotrebnadzor), Obolensk, Russia.
R A AbramovichPeoples' Friendship University of Russia (RUDN University), Moscow, Russia.
J HuwylerDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID 0000-0003-1748-5676
G I El'-RegistanFederal Research Centre "Fundamentals of Biotechnology", Russian Academy of Sciences, Moscow, Russia.
North-Western State Medical University named after I.I. Mechnikov · RURussian Academy of Sciences · RUState Research Center for Applied Microbiology and Biotechnology · RUUniversity of Basel · CHPeoples' Friendship University of Russia · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ever decreasing efficiency of antibiotic treatment due to growing antibiotic resistance of pathogenic bacteria is a critical issue in clinical practice. The two generally accepted major approaches to this problem are the search for new antibiotics and the development of antibiotic adjuvants to enhance the antimicrobial activity of known compounds. It was therefore the aim of the present study to test whether alkylresorcinols, a class of phenolic lipids, can be used as adjuvants to potentiate the effect of various classes of antibiotics. Alkylresorcinols were combined with 12 clinically used antibiotics. Growth-inhibiting activity against a broad range of pro- and eukaryotic microorganisms was determined. Test organisms did comprise 10 bacterial and 2 fungal collection strains, including E. coli and S. aureus, and clinical isolates of K. pneumoniae. The highest adjuvant activity was observed in the case of 4-hexylresorcinol (4-HR), a natural compound found in plants with antimicrobial activity. 50% of the minimal inhibitory concentration (MIC) of 4-HR caused an up to 50-fold decrease in the MIC of antibiotics of various classes. Application of 4-HR as an adjuvant revealed its efficiency against germination of bacterial dormant forms (spores) and prevented formation of antibiotic-tolerant persister cells. Using an in vivo mouse model of K. pneumoniae-induced sepsis, we could demonstrate that the combination of 4-HR and polymyxin was highly effective. 75% of animals were free of infection after treatment as compared to none of the animals receiving the antibiotic alone. We conclude that alkylresorcinols such as 4-HR can be used as an adjuvant to increase the efficiency of several known antibiotics. We suggest that by this approach the risk for development of genetically determined antibiotic resistance can be minimized due to the multimodal mode of action of 4-HR.

Indexed as

Adjuvants, PharmaceuticAnimalsAnti-Bacterial AgentsDisease Models, AnimalDrug Resistance, Multiple, BacterialDrug SynergismDrug Therapy, CombinationEscherichia coliFemaleHexylresorcinolHumansKlebsiella InfectionsKlebsiella pneumoniaeMiceMicrobial Sensitivity TestsPolymyxinsAdjuvants, PharmaceuticAnti-Bacterial AgentsHexylresorcinolPolymyxins

Identifiers

PMID32960928
PMCPMC7508414
OpenAlexW3088064641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.